Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status.

Medical oncology (Northwood, London, England) - 1 Sept 2012

Tiemann Nina, Hildebrandt Guido, Manda Katrin

Abstract excerpt

Panitumumab is the first fully human monoclonal antibody targeting the epidermal growth factor receptor whose clinical use is limited to patients with a non-mutated KRAS status. The aim of this in vitro study was to evaluate whether the KRAS status might influence the cytotoxic and radiosensitizing efficacy of Panitumumab. Exponentially growing cancer cells (HT-29: KRAS wild-type, A549: KRAS mutant) were either...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to DNA Repair
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HT29 Cells

Share to Panitumumab

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 21842425
DOI: 10.1007/s12032-011-0041-7

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status.PMID 21842425Read ↗

Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways.Semantic proximity Read ↗

Combination effect of cetuximab with radiation in colorectal cancer cells.Semantic proximity Read ↗

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.Semantic proximity Read ↗

Autophagy: novel action of panitumumab in colon cancer.Semantic proximity Read ↗

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.Semantic proximity Read ↗

Radioresistance of KRAS/TP53‐mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivoSemantic proximity Read ↗

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).Semantic proximity Read ↗

Effect of cetuximab treatment in squamous cell carcinomas.Semantic proximity Read ↗

Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145.Semantic proximity Read ↗

Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.